LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist
Additionally, they inhibit the secretion of glucagon, a hormone that raises blood sugar levels, and slow gastric emptying, leading to a prolonged feeling of fullness and reduced appetite
While initially approved for Type 2 diabetes, its increasingly prescribed off-label for weight loss due to its strong results
Efficacy and safety of reta, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: A systematic review and meta-analysis of randomized controlled trials
If proven to be safe, retatrutide may benefit individuals suffering from: Hyperphagia (excessive hunger) Hyperglycaemia (high blood glucose) Metabolic syndrome Dyslipidaemia (unhealthy levels of fat in the bloodstream) Non-alcoholic fatty liver disease How Does Retatrutide Work
Ozempic is officieel bedoeld voor de behandeling van type 2 diabetes, maar kan als bijkomend effect gewichtsverlies geven